Taking into account the large phenotypic heterogeneity, our data further support the view that testing for non-CAG trinucleotide repeat CACNA1A mutations should also be performed in patients with non-episodic ataxia of unknown cause. This evidence concerns the gene CACNA1A and Familial paroxysmal ataxia.